Price
No data yet.
Social Signal Score
Company Profile
- CEO
- Jun Xu
- Sector
- Consumer Defensive
- Industry
- Grocery Stores
- Employees
- 329
- Beta
- 4.12
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.68
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
Project earnings forward and see what return today's price implies.
Not enough reported EPS history to estimate growth — this is a placeholder, not an estimate.
- EPS in 5 years
- $4.92
- Implied price
- $73.84
- Return from $1.57
- 116.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $36.71 — today's price is already 95.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | 84.2% | 90.5% | 96.0% | 101.0% | 105.5% |
| 3.0% | 93.6% | 100.2% | 106.0% | 111.2% | 116.0% |
| 8.0% | 103.0% | 109.9% | 116.0% | 121.5% | 126.5% |
| 13.0% | 112.4% | 119.6% | 126.0% | 131.7% | 137.0% |
| 18.0% | 121.8% | 129.4% | 136.0% | 142.0% | 147.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
90Social Signal Score
Mentions (1)
- Newsglobenewswire.com·1d ago·Negative
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics…
View source ↗
Earnings
Mon, Sep 28(in 6 weeks)
Consensus estimate $0.57 per share
Typical surprise -400.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Mar 17$-8.00 vs $1.00miss
- Mon, Dec 15$-11.50 vs $-2.30miss
- Mon, Sep 22$-4.00 vs $-4.00beat
Estimates and results for MSS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MSS officers and directors.
- Bought
- $58k
- Sold
- $225k
9 trades
4 trades
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpbought
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Xu Johnbought
- Xu Johnbought
8 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.